Results Preview: Scrip's Pharma Watchlist
This article was originally published in Scrip
Johnson & Johnson will kick off the big pharma financial results season on Jan. 26. The backdrop for the company's conference call on its earnings will be the restructuring of its medical devices business. On Jan. 19 it announced it would cut around 3,000 jobs to make savings of $800m-1bn. That will involve one-off charges of $2-2.4bn with about $600m to be lodged in the books of the fourth quarter just gone. J&J has promised additional details of the impact of its changes during its earnings call.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.